Search results for "ASPIRIN"

showing 10 items of 146 documents

Moderne Therapie bei akutem Koronarsyndrom

2002

Inhibition of platelet aggregation with aspirin and anticoagulation with unfractionated heparin can be considered the gold standard treatment of patients with acute coronary syndromes. Replacement of unfractionated heparins by low-molecular weight heparins seem to further improve the cardiovascular risk. Additional treatment with glycoprotein IIb/IIIa receptor blockers led to a further reduction of the clinical event rate, especially in patients undergoing coronary interventions during an acute coronary syndrome (more than 30% relative risk reduction). However, the latter substances did only lead to marginal improvements in the setting of a conservative stabilization of patients with acute …

Relative risk reductionAcute coronary syndromeAspirinmedicine.medical_specialtybusiness.industryUnstable anginaGeneral Medicinemedicine.diseaseClopidogrelCoronary artery diseaseAnginaInternal medicineCardiologyMedicineMyocardial infarctionbusinessmedicine.drugMedizinische Klinik
researchProduct

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chron…

2022

Guglielmo Mantica,1 Francesco Chierigo,1,2 Farzana Cassim,3 Francesca Ambrosini,1,2 Stefano Tappero,1,2 Rafaela Malinaric,1,2 Stefano Parodi,1,2 Andrea Benelli,4 Federico Dotta,4 Marco Ennas,4 Martina Beverini,1,2 Chiara Vaccaro,5 Salvatore Smelzo,6 Giovanni Guano,1,2 Federico Mariano,1,2 Calogero Paola,1,2 Giorgia Granelli,1,2 Virginia Varca,5 Carlo Introini,4 Salvatore Dioguardi,7 Alchiede Simonato,7 Andrea Gregori,8 Franco Gaboardi,6 Carlo Terrone,1,2 André Van der Merwe3 1IRCCS Ospedale Policlinico San Martino, U.O. Urologia, Genova, Italy; 2Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy; 3Department of Urology, Tygerberg Academic …

Research and Reports in UrologyaspirininflammationUrologyprostate-specific antigenprostate biopsyprostate cancer
researchProduct

Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005

2007

Purpose To examine the recent epidemiological studies on aspirin use and breast cancer risk published from 2001 to 2005 within a meta-analysis, to investigate reasons for heterogeneity between the individual studies and to analyse a dose-response-relationship considering frequency and duration of use. Methods We systematically searched for cohort-studies and case-control-studies from 2001–2005, which evaluated the association between aspirin and breast cancer risk. We calculated a pooled estimate for the relative risk (RR) and investigated reasons for heterogeneity between the individual studies and analysed a dose-response-relationship using random effects mixed models. Results We identifi…

RiskOncologymedicine.medical_specialtyEpidemiologyBreast NeoplasmsDrug Administration ScheduleBreast cancerInternal medicineEpidemiologymedicineHumansPharmacology (medical)Meta-regressionAspirinModels StatisticalAspirinDose-Response Relationship Drugbusiness.industryAnti-Inflammatory Agents Non-SteroidalReproducibility of Resultsmedicine.diseaseRandom effects modelSurgeryMeta-analysisRelative riskRegression AnalysisFemaleObservational studyControlled Clinical Trials as Topicbusinessmedicine.drugPharmacoepidemiology and Drug Safety
researchProduct

Rivaroxaban in Peripheral Artery Disease after Revascularization

2020

Abstract Background Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and ...

RivaroxabanAspirinmedicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentGeneral MedicineDisease030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trialMulticenter studylawInternal medicineCardiologyMedicine030212 general & internal medicinebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study

2019

Patients with established cardiovascular disease may suffer further cardiovascular events, despite receiving optimal medical treatment. Although platelet inhibition plays a central role in the prevention of new events, the use of anticoagulant therapies to reduce events in atheromatous disease has, until recently, been overlooked. The recent Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) study showed an important reduction in cardiovascular events without increasing the risk of fatal and intracranial bleeding when using rivaroxaban, a novel oral anticoagulant, combined with aspirin. This article reviews the available evidence…

Rivaroxabanmedicine.medical_specialtyAspirinmedicine.drug_classbusiness.industryArterial diseaseAnticoagulantDisease030204 cardiovascular system & hematologymedicine.diseaseThrombosisPharmacotherapyPeripheralClinical Practice03 medical and health sciences0302 clinical medicinemedicine030212 general & internal medicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessmedicine.drugEuropean Cardiology Review
researchProduct

Verlängerte Sekundärprophylaxe nach venöser Thromboembolie

2018

Was ist neu? Aktuelle Studien Kurz nach Absetzen der oralen Antikoagulation kommt es zu einem etwa 2- bis 3-fachen Anstieg von VTE-Rezidiven. Das Rezidivrisiko ist besonders hoch nach einer VTE, die ohne identifizierbaren Auslöser aufgetreten war oder wenn nur weiche, unsichere auslösende Risikofaktoren vorlagen, sowie bei fortbestehenden Risikofaktoren, wie z. B. einer Krebserkrankung. Konsensusdokument über auslösende Risikofaktoren für venöse Thromboembolie In einem aktuellen Konsensusdokument wurden die zugrundeliegenden Risikofaktoren definiert und in 3 Gruppen klassifiziert. Direkte orale Antikoagulanzien Eine reduzierte Dosis von DOAK ermöglicht eine wirksame verlängerte Sekundärprop…

Secondary preventionmedicine.medical_specialtyAspirinbusiness.industryDosing regimenGeneral Medicine030204 cardiovascular system & hematologyDiscontinuation03 medical and health sciencesRegimenTraffic signal0302 clinical medicineInternal medicinemedicine030212 general & internal medicineRisk factorbusinessVenous thromboembolismmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Stroke subtypes and their possible implication in stroke prevention drug strategies

2014

Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of the renin-angiotensin aldosterone system (RAAS) may have beneficial effects beyond the…

TOAST ClassificationDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectBlood PressureStroke subtype preventionInternal medicinemedicineAnimalsHumanscardiovascular diseasesStrokeAntihypertensive AgentsRandomized Controlled Trials as Topicmedia_commonPharmacologyAspirinbusiness.industryDipyridamoleAtherosclerosismedicine.diseaseSurgeryStrokeDipyridamoleClinical trialBlood pressureCardiologyCardiology and Cardiovascular MedicineComplicationbusinessLipohyalinosisPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Fabrication, characterization, thermal stability and nanoassemblies of novel pullulan-aspirin conjugates

2017

Abstract Present study deals with homogeneous and one-pot synthesis of novel macromolecular prodrugs (MPDs) of aspirin onto naturally occurring hydrophilic biopolymer pullulan. Pullulan-aspirin conjugates were synthesized by using green carboxylic acid activating reagent 1,1′-carbonyldiimidazole (CDI). The aspirin was first reacted with CDI to prepare aspirin-imidazolide at RT for 24 h which in situ reacted with pre-dissolved pullulan and the reaction preceded further for 24 h at 80 °C under nitrogen. Degree of substitution (DS 0.32–0.40) of aspirin onto pullulan was calculated from 1H NMR spectroscopy. Spectroscopic techniques confirmed the high covalent drug loading and purity. Thermal an…

Thermal propertiesChemistry(all)General Chemical EngineeringCarboxylic acid02 engineering and technologyengineering.material010402 general chemistry01 natural scienceslcsh:Chemistrychemistry.chemical_compoundBiopolymersAmphiphileOrganic chemistryThermal stabilitychemistry.chemical_classificationAspirinEsterificationPullulanGeneral ChemistryProdrug021001 nanoscience & nanotechnologyCombinatorial chemistry0104 chemical scienceschemistrylcsh:QD1-999Covalent bondReagentengineeringChemical Engineering(all)NanoparticlesBiopolymer0210 nano-technologyPullulan-aspirin conjugatesArabian Journal of Chemistry
researchProduct

Are Anticoagulants and Antiplatelet Agents Important in Thoracic Surgery?

2020

The management of antithrombotic drugs (antiplatelet and anticoagulant agents) is a common challenging issue in patients undergoing thoracic surgery. The procedure can require the temporary interruption of these drugs because of their associated haemorrhagic risk, therefore assuming a thrombotic risk also. The assessment of the balance between both risks gives us their optimal management.

Thrombotic riskAspirinmedicine.medical_specialtyCardiothoracic surgerybusiness.industryAntithromboticmedicineAnticoagulant AgentIn patientIntensive care medicinebusinessOptimal managementmedicine.drug
researchProduct

Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. T…

2017

Background Type 2 diabetes mellitus (T2DM) is one of the most common causes of chronic kidney disease and kidney failure. It has been estimated that the annual decline of estimated glomerular filtration rate (eGFR) among patients with T2DM is approximately 2.0-2.5 mL min−1 y−1. Cyclooxygenase-dependent eicosanoids, such as 11-dehydro-thromboxane (Tx)B2, are increased in T2DM patients and are potentially involved in the regulation of renal blood flow. Animal models showed that cyclooxygenase inhibitors, such as aspirin, are associated with improvements in renal plasma flow and eGFR values. Hypothesis The primary end point of the LEDA trial is to evaluate the 1-year decline of eGFR in T2DM pa…

Time Factorskidney disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineRenal Insufficiency030212 general & internal medicineChronicKidneyAspirinkidney disease progressionclinical trialtrialPrognosisType 2 diabetes mellituAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus Type 2; Disease Progression; Dose-Response Relationship Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency Chronic; Time Factors; Cardiology and Cardiovascular Medicinemedicine.anatomical_structureAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus; Type 2; Disease Progression; Dose-Response Relationship; Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency; Chronic; Time Factors; Cardiology and Cardiovascular MedicineDisease Progressiontype 2 diabetesDrugSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyUrologyRenal functionDose-Response Relationship03 medical and health sciencesDouble-Blind MethodDiabetes MellitusHumansCyclooxygenase InhibitorsRenal Insufficiency Chronickidney disease kidney disease progression type 2 diabetes aspirin trialDose-Response Relationship DrugAspirinbusiness.industryrenal functionmedicine.diseaseSurgeryClinical trialDiabetes Mellitus Type 2Renal blood flowbusinessFollow-Up StudiesKidney disease
researchProduct